{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-318853","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2026-07-28T11:13:43+00:00","discovered_at":"2026-07-28T11:15:01.355757+00:00","generated_at":"2026-07-28T11:15:17.438366+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Repligen Q2 revenue $204M (+13% organic), adj EPS $0.54; raises FY guidance; acquires BioLife","bullets":["Q2 revenue $204M, +12% reported, +13% organic; adjusted EPS $0.54 vs $0.37 prior year.","GAAP operating income flat at $14M; GAAP EPS $0.09 (down from $0.26).","Full year 2026 guidance raised: organic growth 10.5%-13.5%, adjusted EPS $2.03-$2.09.","Announced definitive agreement to acquire BioLife Solutions, strengthening cell therapy position.","Cash and marketable securities $810M at June 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-318853","json":"https://secwatch.observer/filing/0001193125-26-318853.json","markdown":"https://secwatch.observer/filing/0001193125-26-318853.md","text":"https://secwatch.observer/filing/0001193125-26-318853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000119312526318853/0001193125-26-318853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000119312526318853/rgen-20260728.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-28T11:15:17.438366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}